Altre lingue Oragenics, Inc.

Azioni

Mercato chiuso - Nyse Altri mercati azionari 22:10:00 03/05/2024			Variaz. 5gg	Var. 1 gen.
1,07 ^USD	+1,90%		+3,88%	-80,98%

29/03	Oragenics, Inc. riporta i risultati degli utili per l'intero anno terminato il 31 dicembre 2023	CI
18/03	Oragenics nomina James Kelly MD come Chief Medical Officer, per guidare gli studi clinici di Fase II per il trattamento della commozione cerebrale	CI

Oragenics, Inc. Announces Notification of Noncompliance with Additional NYSE American Continued Listing Standards	19/04
North American Morning Briefing : Big Banks Kick -2-	12/04
Oragenics, Inc. Files 10K and Provides Company Update	01/04
Oragenics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	29/03
Oragenics Appoints James Kelly MD, Chief Medical Officer, to Lead Phase II Clinical Trials for Treating Concussion	18/03
Oragenics Appoints James Kelly MD as Chief Medical Officer, to Lead Phase II Clinical Trials for Treating Concussion	18/03
Oragenics, Inc. Prepares Drug for Phase II Clinical Trials to Treat Concussion	05/03
Oragenics, Inc. Prepares Drug for Phase II Clinical Trials to Treat Concussion	05/03
Oragenics Announces Closing of Public Offering	04/03
Oragenics Announces Closing of Public Offering	01/03
Top Midday Decliners	28/02
Oragenics Announces Pricing of Public Offering	28/02
Oragenics Announces Proposed Public Offering	27/02
Oragenics CEO Kimberly Murphy Steps Down, Board Chair to Serve as Interim Executive Chair	13/02
Oragenics, Inc. Announces Leadership Transition	12/02
Oragenics, Inc. Announces Leadership Transition	12/02
Oragenics, Inc. Announces CEO Changes	12/02
Oragenics, Inc. Announces Expiration of Its Investment Banking Engagement Agreement	07/02
Oragenics, Inc. Preparing for Phase II Clinical Trials to Treat Concussion	05/02
Oragenics, Inc. Prepares for Phase II Clinical Trials to Treat Concussion	05/02

Non ci sono risultati per questa ricerca